Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 1118-1128

  Tiraloche, Gabrielle ^a   Girard, Christiane ^a   Chouinard, Luc ^b   Sampalis, John ^c   Moquin, Luc ^a   Ionescu, Mirela ^d   Reiner, Agnes ^d   Poole, A Robin ^d   Laverty, Sheila ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ClinTrials BioResearch Ltd   (Canada)

^c JSS Medical Research   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GLUCOSAMINE; GLYCOSAMINOGLYCAN; PLACEBO; PROTEOGLYCAN;

ANIMAL MODEL; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; ARTICULAR CARTILAGE; BONE EROSION; CARTILAGE DEGENERATION; FEMUR CONDYLE; HISTOLOGY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RABBIT; STAINING; TIBIA TUBEROSITY;

ADMINISTRATION, ORAL; ANIMALS; ANTERIOR CRUCIATE LIGAMENT; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; CELL COUNT; CHONDROCYTES; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; GLUCOSAMINE; GLYCOSAMINOGLYCANS; MALE; OSTEOARTHRITIS; RABBITS; STIFLE;

EID: 17244378123     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20951     Document Type: Article

References (54)

1. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
2. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
3. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
4. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis [review]. Cochrane Database Syst Rev 2001;1:CD002946.
5. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22.
6. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.
7. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002;41:279-84.
8. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
10. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
11. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 2004;12:263-8.
12. Altman RD. Measurement of structure (disease) modification in osteoarthritis. Osteoarthritis Cartilage 2004;12 Suppl A:S69-76.
13. Towheed TE. Current status of glucosamine therapy in osteoarthritis [review]. Arthritis Rheum 2003;49:601-4.
14. Adebowale A, Cox D, Liang Z, Eddington N. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. JANA 2000;3:37-43.
15. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002;29:2407-9.
16. Hulth A, Lindberg L, Telhag H. Experimental osteoarthritis in rabbits: preliminary report. Acta Orthop Scand 1970;41:522-30.
17. Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 2000:229-40.
18. Hulmes DJ, Marsden ME, Strachan RK, Harvey RE, McInnes N, Gardner DL. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage 2004;12:232-8.
19. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002;46:2495-503.
20. McDaniel WJ Jr, Dameron TB Jr. The untreated anterior cruciate ligament rupture. Clin Orthop 1983;172:158-63.
21. Sonoda M, Harwood FL, Amiel ME, Moriya H, Amiel D. The effects of hyaluronan on the meniscus in the anterior cruciate ligament-deficient knee. J Orthop Sci 2000;5:157-64.
22. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol 2000;27:1713-20.
23. Oegema T, Visco D. Animal models of osteoarthritis. In: Friedman RJ, editor. Animal models in orthopaedic research. Boca Raton (FL): CRC Press; 1999. p. 349-67.
24. Poole AR, Nelson F, Dahlberg L, Tchetina E, Kobayashi M, Yasuda T, et al. Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp 2003;70:115-23.
25. Kojima T, Mwale F, Yasuda T, Girard C, Poole AR, Laverty S. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001;44:120-7.
26. Yoshioka M, Coutts R, Amiel D, Hacker S. Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 1996;4:87-98.
27. Carlson CS, Loeser RF, Purser CB, Gardin JF, Jerome CP. Osteoarthritis in cynomolgus macaques. III. Effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res 1996;11:1209-17.
28. Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 1996;4:99-110.
29. Mankin H, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;73:1301-15.
30. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
31. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32.
32. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophys Acta 1986;883:173-7.
33. McDevitt C, Gilbertson E, Muir H. An experimental model of osteoarthritis: early morphological and biochemical changes. J Bone Joint Surg Br 1977;59:24-35.
34. Le Graverand MP, Eggerer J, Vignon E, Otterness IG, Barclay L, Hart DA. Assessment of specific mRNA levels in cartilage regions in a lapine model of osteoarthritis. J Orthop Res 2002;20:535-44.
35. Ilic MZ, Martinac B, Handley CJ. Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. Osteoarthritis Cartilage 2003;11:613-22.
36. De Mattei M, Pellati A, Pasello M, de Terlizzi F, Massari L, Gemmati D, et al. High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cartilage 2002;10:816-25.
37. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. The effects of glucosamine derivatives on equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:444-51.
38. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:258-65.
39. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human Osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003;11:424-32.
40. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998;6:427-34.
41. Sandy J, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
42. Byron CR, Orth MW, Venta PJ, Lloyd JW, Caron JP. Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide- stimulated equine chondrocytes. Am J Vet Res 2003;64:666-71.
43. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003;11:290-8.
44. Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett 2002;510:166-70.
45. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 2001;166:5155-60.
46. Piperno M, Reboul P, Hellio le Graverand MP, Peschard MJ, Annefeld M, Richard M, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000;8:207-12.
47. Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005;52:181-91.
48. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 2001;51:699-725.
49. McClain DA, Paterson AJ, Roos MD, Wei X, Kudlow JE. Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A 1992;89:8150-4.
50. Hsieh TJ, Fustier P, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003;144:4338-49.
51. Rumberger JM, Wu T, Hering MA, Marshall S. Role of hexosamine biosynthesis in glucose-mediated up-regulation of lipogenic enzyme mRNA levels: effects of glucose, glutamine, and glucosamine on glycerophosphate dehydrogenase, fatty acid synthase, and acetyl-CoA carboxylase mRNA levels. J Biol Chem 2003;278:28547-52.
52. Wang S, Laverty S, Stuart K, White L, Plaas A, Grynpas M. The effects of glucosamine on the bone in a rabbit model of osteoarthritis. In: Transactions of the 50th Annual Meeting Orthopaedic Research Society Vol. 29, San Francisco (CA): March 7-10, 2004. no. 936.
53. Chard J, Dieppe P. Glucosamine for Osteoarthritis: magic, hype, or confusion? It's probably safe: but there's no good evidence that it works. BMJ 2001;322:1439-40.
54. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001;50:767-70.